Loomis, Sayles & Company
IART icon

Loomis, Sayles & Company’s Integra LifeSciences IART Stock Holding History

Loomis, Sayles & Company’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-202
Closed -$9K – 825
2023
Q4 		$9K Buy
+202
New +$7.95K ﹤0.01% 806
2017
Q4 		– Sell
-176
Closed -$9K – 887
2017
Q3 		$9K Sell
176
-353
-67% -$18.1K ﹤0.01% 797
2017
Q2 		$29K Sell
529
-191
-27% -$9.12K ﹤0.01% 700
2017
Q1 		$30K Sell
720
-334,136
-100% -$14.3M ﹤0.01% 699
2016
Q4 		$14.4M Sell
334,856
-269,530
-45% -$11M 0.04% 348
2016
Q3 		$24.9M Sell
604,386
-17,992
-3% -$754K 0.06% 200
2016
Q2 		$24.8M Sell
622,378
-73,068
-11% -$2.63M 0.07% 212
2016
Q1 		$23.4M Buy
695,446
+194,988
+39% +$6.07M 0.07% 213
2015
Q4 		$17M Buy
+500,458
New +$15.6M 0.05% 329

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company's IART Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Integra LifeSciences (IART) in Q1 2024, closing a stake of 202 shares — an estimated $9K sold.

Loomis, Sayles & Company first reported a position in IART in Q4 2015 and held it in 9 quarters. The position peaked at $24.9M in Q3 2016. 281 funds tracked by Wall St. Rank hold IART as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Integra LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 202 Integra LifeSciences shares in Q1 2024, an estimated $9K.
  • Loomis, Sayles & Company first reported a position in Integra LifeSciences in Q4 2015 and held it in 9 quarters.
  • Loomis, Sayles & Company's Integra LifeSciences position peaked at $24.9M in Q3 2016.
  • 281 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.